ComboMATCH is a precision medicine initiative sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health. A unique initiative to test new combinations of cancer drugs guided by tumor biology, ComboMATCH aims to pair patients with locally advanced or advanced solid tumors with a therapy that has the potential to manage their cancer. The study will also assist physicians in devising more effective treatment strategies. ComboMATCH is led by the ECOG-ACRIN Cancer Research Group and the NCI through the National Clinical Trials Network (NCTN). ComboMATCH treatment trials are conducted by the NCI funded NCTN research groups in the United States.

These include the Alliance for Clinical Trials in Oncology, Children’s Oncology Group, ECOG-ACRIN Cancer Research Group, NRG Oncology, and SWOG Cancer Research Network. To learn more about ComboMATCH, visit:

• https://ecog-acrin.org/combomatch
• https://www.cancer.gov/research/infrastructure/clinical-trials/featured/combomatch

sïParadigm Diagnostic Informatics is a premier specialty reference laboratory and diagnostic healthcare company headquartered in Pine Brook, New Jersey.

Founded in 2004, the laboratory provides advanced diagnostic services to physicians, hospitals, and oncology practices across the United States and globally.

sïParadigm is a leader in the shift toward biomarker-driven medicine, specializing in high-complexity testing that transforms raw biological data into actionable clinical insights for cancer treatment and patient management.

Our mission is to make comprehensive biomarker profiling accessible to all patients, eliminating logistical and financial barriers to precision medicine.

We are committed to a "patient-first" approach, delivering diagnostic results with the highest quality and industry-leading turnaround times (TAT) to ensure timely, data-driven therapeutic decisions.

sïParadigm offers a multi-omics approach to diagnostics, integrating genomic (DNA), transcriptomic (RNA), and proteomic data. Our clinical expertise includes:

• Precision Oncology: Comprehensive solid tumor molecular profiling and liquid biopsy testing.
• Hematopathology: Specialized diagnostic services for blood-based cancers and disorders.
• Advanced Methodologies: Expertise in Next-Generation Sequencing (NGS), Flow Cytometry, Fluorescence In Situ Hybridization (FISH), Cytogenetics, Immunohistochemistry (IHC), and PCR.
• Biomarker Signature Analysis: Identification of rare driver mutations and genomic instability markers (such as HRD, TMB, and MSI) to guide targeted therapies and clinical trial eligibility.
• Diagnostic Informatics: Utilization of proprietary software and AI to streamline specimen tracking, kit ordering, and physician reporting.

We maintain the highest standards of quality and regulatory compliance, holding the following key credentials:

• CLIA Certification: Fully certified under the Clinical Laboratory Improvement Amendments (CLIA ID: 31D1028659 ).
• CAP Accreditation: Accredited by the College of American Pathologists (CAP), the gold standard in laboratory quality assurance.
• State Licensures: Licensed in various states with rigorous requirements, including New Jersey, California, New York, Maryland, Pennsylvania, and Rhode Island.
• HIPAA Compliant: Adherence to strict federal guidelines for the protection of patient privacy and health information.

For more information, visit our website at www.sïParadigm.com.